TrialsgrambetaRCTs are beautiful

SUMMIT (COPD)

2016

Study to Understand Mortality and Morbidity in COPD

In 16,485 patients with moderate COPD and CVD or high CV risk, fluticasone furoate-vilanterol did not reduce all-cause mortality compared with placebo.

Result

Efficacy: All-cause mortalityHR 0.88 (95% CI 0.74-1.04) · P = 0.137

Below 1 favours fluticasone furoate-vilanterol, above 1 favours placebo.

Also reported: No effect on the composite CV outcome.

Original publication
Subtopic
ICS/LABA, CV risk
Design
Multicentre RCT, 4-arm
Relevance
Supporting: context rather than must-know.
Source
Vestbo J, et al. Lancet. 2016;387(10030):1817-1826.doi 10.1016/S0140-6736(16)30069-1

Discussion & critique

Definitive negative trial of ICS/LABA mortality benefit in CV-enriched COPD; directly relevant to cardiology consultation.